latest news


Cerdanyola del Vallès (Barcelona), 17 November 2016 –CRO KYMOS Pharma Services has

closed a deal to acquire Italian firm Pharmaprogress, located in Ancona (in the Marche region of

Italy) with a 700-m² analysis laboratory, staff of 10 and estimated turnover of €1 million for 2017.

Pharmaprogress has GMP authorisation from the Italian Medicines Agency and is very well

positioned among top pharmaceutical companies in the country.

“This acquisition helps us make Italy our main foreign market, followed closely by France, and to

speed up the expansion plans we began five years ago to consolidate our place as an important

CRO in the European market,” says Joan Puig de Dou, CEO of KYMOS Pharma Services.

KYMOS’s main markets today are Italy, France, Switzerland, Germany and Portugal.

The acquisition of Pharmaprogress is important because the national and foreign pharmaceutical

industry is highly present in Italy, "with great potential for outsourcing, so we can expect to provide

current Pharmaprogress clients a wider range of services, particularly in the field of

biotechnology products, as well as greater capacity for project management," explains Puig de


KYMOS Pharma Services puts its exports at nearly 50% of all turnover and expects to see €7

million in sales in 2016, with EBITDA at 20%.


About KYMOS Pharma Services

KYMOS Pharma Services, founded in 2001, is a private Contract Research Organisation (CRO)

that provides R&D and quality-control services for the biotechnology, pharmaceutical, veterinary,

phytosanitary, nutraceutical and cosmetics industries.

The most important milestones in the company's recent history include a strategic deal with French

multinational corporation Ipsen in 2012, the inauguration of its new laboratories at the Vallès

Technology Park (Cerdanyola del Vallès) in 2015 and, now, the acquisition of Pharmaprogress in


Kymos has a team of 80 highly qualified professionals, 70% of which hold undergraduate or

graduate degrees in Chemistry, Pharmacy, Biochemistry or Biology.


About Phamaprogress

Phamaprogress is a private CRO that is firmly established in the Italian pharmaceutical market,

offering bioanalysis and quality-control services for drugs. It was founded in 2001 by a former

executive in the Angellini group, Dr. Depalmo Galli, who continues to collaborate with the


25 julyRenewal of permission for the production

Obtaining, after the inspection of the general revision 15-16-17 December 2010, the renewal of the authorization for production in accordance with Good Manufacturing Practice (GMP or GMP).

Authorized activities:

Production activities

1.6 Tests for quality control

1.6.3 Chemical / Physical

Authorized activities:

Production activities for experimental drugs

1.6 Tests for quality control

1.6.3 Chemical / Physical


Analisi dei principi attivi